BCL2 and non-small cell lung carcinoma: Lu et al. found that in NSCLC, the trans-3,5,4′-trimethoxystilbene could inhibit the MAPK/Akt/Bcl-2 axis by upregulating miR-345 and miR-498, further reducing gefitinib resistance [28].